Donepezil: In Vascular Dementia

Drugs and Aging

Volumn 20, Issue 15, 2003, Pages 1127-1136

  Goldsmith, David R ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; ANOREXIA; BRADYCARDIA; CLINICAL TRIAL; COGNITION; DIARRHEA; DRUG MECHANISM; DRUG TOLERABILITY; HEADACHE; HUMAN; INJURY; INSOMNIA; LEG CRAMP; MICROANGIOPATHY; MULTIINFARCT DEMENTIA; NAUSEA; PRIORITY JOURNAL; REVIEW; RHINITIS; SCORING SYSTEM; STROKE; SYNCOPE; TRANSIENT ISCHEMIC ATTACK; VOMITING;

ADMINISTRATION, ORAL; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; DEMENTIA, VASCULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDANS; PIPERIDINES; PSYCHIATRIC STATUS RATING SCALES;

EID: 0346786223     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200320150-00005     Document Type: Review

References (29)

1. Román GC. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med Clin North Am 2002 May; 86 (3): 477-99
2. Pratt RD. Patient populations in clinical trials of the efficacy and tolerability of donepezil in patients with vascular dementia. J Neurol Sci 2002 Nov; 203-204: 57-65
3. Bonner LT, Peskind ER. Pharmacologic treatments of dementia. Med Clin North Am 2002 May; 86 (3): 657-74
4. Bowler JV. Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease. Stroke 2003 Feb; 34 (2): 584-6
5. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993 Feb; 43 (2): 250-60
6. Gueyffier F, Boissel J, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Stroke 1997 Dec; 28 (12): 2557-62
7. Pratt RD, Perdomo CA. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Ann N Y Acad Sci 2002 Nov; 977: 513-22
8. Amenta F, Di Tullio MA, Tomassoni D. The cholinergic approach for the treatment of vascular dementia: evidence from pre-clinical and clinical studies. Clin Exp Hypertens 2002 Oct-Nov; 24 (7-8): 697-713
9. Dooley M, Lamb H. Donepezil: a review of its use in Alzheimer's disease. Drugs Aging 2000 Mar; 16 (3): 199-226
10. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41 (10): 719-39
11. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001; 15 (5): 375-90
12. Rogers S, Farlow M, Doody R, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998 Jan; 50 (1): 136-45
13. Meyer JS, Chowdhury MH, Xu G, et al. Donepezil treatment of vascular dementia. Ann N Y Acad Sci 2002 Nov; 977: 482-6
14. Li Y, Meyer JS, Haque MA, et al. Feasibility of vascular dementia treatment with cholinesterase inhibitors [letter]. Int J Geriatr Psychiatry 2002 Feb; 17 (2): 194-6
15. Sisak E. Donepezil treatment in vascular dementia [abstract]. 2nd International Congress on Vascular Dementia; 2002 Jan 24-27; Salzburg [online]. Available from URL: http://www.kenes.com/abstracts/vas01/73.doc [Accessed 2003 Mar 21]
16. Mendez MF, Younesi FL, Perryman KM. Use of donepezil for vascular dementia: preliminary clinical experience. J Neuropsychiatry Clin Neurosci 1999 Spring; 11 (2): 268-70
17. Black S, Román GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34 (10): 2323-32
18. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003 Aug; 61 (4): 479-86
19. Salloway S, Pratt RD, Perdomo CA, et al. Donepezil-treated patients with vascular dementia demonstrate cognitive and global benefits: results from Study 308, a 24-week, randomized, double-blind, placebo-controlled trial [abstract no. 219]. Neurobiol Aging 2002 Jul-2002 31; 23 Suppl. 1: S57
20. Salloway SP, Pratt RD, Perdomo CA. Donepezil improves cognition both in patients with probable and those with possible vascular dementia [abstract no. P3114]. Eur J Neurol 2002; 9 Suppl. 2: 192
21. Geldmacher DS, Pratt RD, Perdomo CA. Donepezil slows functional deterioration in patients with vascular dementia [abstract no. SC229]. Eur J Neurol 2002; 9 Suppl. 2: 35
22. Perdomo CA, Pratt RD. A comparison of the effects of donepezil in patients with probable and possible vascular dementia: a combined analysis of two 24-week, randomized, double-blind, placebo-controlled trials [abstract no. P05.115]. Neurology 2002 Apr; 58 Suppl. 3: A382
23. Doody R, Pratt R, Perdomo C, et al. Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: a comparison of Alzheimer's disease versus vascular dementia [abstract no. S48.002]. Neurology 2003 Mar; 60 Suppl. 1: A412
24. Pratt R, Perdomo C. Population characteristics of patients with VaD [abstract no. PO-45-21]. 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan, 230
25. Pratt R, Perdomo C, Donepezil 307 and 308 Study Groups. Donepezil is well tolerated in patients with vascular dementia: a comparison of safety and tolerability results from randomized, placebo-controlled clinical trials in vascular dementia patients and Alzheimer's disease patients [abstract no. 218]. Neurobiol Aging 2002 Jul-Aug; 23 Suppl. 1: S57
26. Black S, Pratt R, Perdomo C, et al. Donepezil is well tolerated in patients with vascular dementia [abstract no. P318]. Stroke 2003 Jan; 34 (1): 314
27. Salloway SP, Pratt RD, Perdomo CA. Donepezil is well tolerated in patients with vascular dementia: a comparison of tolerability in vascular dementia patients and Alzheimer's disease patients [abstract no. P3122]. Eur J Neurol 2002; 9 Suppl. 2: 194
28. Black S, Pratt R, Perdomo C, et al. Donepezil provides significant benefits on cognition and global function in patients with probable vascular dementia [abstract no. 78]. Stroke 2003 Jan; 34 (1): 252
29. Eisai Inc. U.S. Prescribing information: Aricept® (donepezil hydrochloride tablets) [online]. Available from URL: http:// www.aricept.com/pi/aricept_pi.htm [Accessed 2003 Jul 1]